Avonex Articles
Stock Commentary - New York
3 June 2002
Serono drops drug for rheumatoid arthritis
3 June 2002
Biogen gets backing for psoriasis drug Amevive
3 June 2002
Stock Commentary - Europe
27 May 2002
Avonex gets EU OK for high-risk MS patients
27 May 2002
US Medicaid not to cover Serono
27 May 2002
Stock Commentary - Europe
6 May 2002
Stock Commentary - New York
29 April 2002
Serono reports 10.4% 1st-qtr sales increase
29 April 2002
Biogen hits back at Serono with new study
29 April 2002
Stock Commentary - Europe
15 April 2002
Serono seeks to overturn Berlex patent
25 March 2002
Stock Commentary - Europe
18 March 2002
Stock Commentary - New York
18 March 2002
CPMP backs Avonex for early-stage MS
11 March 2002
Fast-track MS drug plan for the UK
25 February 2002
Serono's 2001 5.2% net income rise below consensus forecasts
18 February 2002
UK deal cuts MS drug prices by up to 26%
11 February 2002
Biogen planning clinical trials of Amevive in Japan
11 February 2002
UK govt/industry agree risk-share drug deal for MS
11 February 2002
Stock Commentary - Europe
4 February 2002
Biogen earnings hit by charges but revenues reach $1 billion
4 February 2002
Biogen and Schering AG settle in Avonex patent dispute
28 January 2002
Biogen predicting steady growth
14 January 2002
Rebif panel meeting in USA cancelled
7 January 2002
Biogen forecasts revenues over $1 billion for 2001
7 January 2002
Elan and Biogen initiate Phase III trial for Antegren
7 January 2002
Rebif panel meeting in USA cancelled
27 December 2001
Biogen forecasts revenues over $1 billion for 2001
24 December 2001
Elan and Biogen initiate Phase III trial for Antegren
20 December 2001
Net income up 23% at Schering AG as Betaferon sales stay strong
9 November 2001
Stock Commentary - New York
8 November 2001
Serono reports disappointing sales
31 October 2001
Avonex revenues up 29% at Biogen
16 October 2001
Schering AG claims upper hand in MS drug trial
10 October 2001
Serono files amendment to Rebif BLA in USA
8 October 2001
Celltech to merge with Biogen?
5 October 2001
Elan and Biogen's Antegren to start Phase III trials in MS
17 September 2001
NICE PAD on MS drugs calls for talks on prices
7 August 2001
Update - dip in 2nd-qtr net income for Biogen
18 July 2001
Dip in 2nd-qtr net income for Biogen
17 July 2001
Biogen, Serono in court over interferon spat
12 July 2001
Stock Commentary - Europe
5 July 2001
Stock Commentary - New York
28 June 2001
Promising Ph III results for Biogen's Amevive
13 June 2001
Pharma "now 71.5% of Israeli biotech sales"
25 May 2001
Biogen investing $350 million in Denmark
16 May 2001
Stock Commentary - New York
10 May 2001
Stock Commentary - Europe
10 May 2001
Serono makes strong start to 2001
2 May 2001
Biogen net income down 40% in 1st qtr
17 April 2001
Biogen net income down 40% in 1st qtr
12 April 2001
Stock Commentary - Europe
8 February 2001
EU approves highest dose of Serono's Rebif
5 February 2001
Further delays to NICE MS drug appraisal
31 January 2001
Positive Ph II for Elan/ Biogen's Antegren
24 January 2001
Rebif pushes Serono sales up 16.2%
23 January 2001
Biogen reports much-anticipated Avonex results in SPMS
18 January 2001
Vaccines acquisition set to drive near-term growth at PowderJect
12 December 2000
Betaferon beats rivals to Japanese market
28 November 2000
Rebif: Serono slams Biogen's "incorrect" statements
16 November 2000
Stock Commentary - Europe
16 November 2000
Serono wins injunction in Dutch interferon dispute
8 November 2000
Inhale pulls plans to buy Quadrant
6 November 2000
Serono third-quarter earnings leap 83%
24 October 2000
Biogen begins long-term Avonex study
19 October 2000
Avonex sales disappoint in USA, according to analysts
11 October 2000
Stock Commentary New York
21 September 2000
Stock Commentary New York
7 September 2000
Copaxone study shows six-year efficacy
23 August 2000
Biogen, Elan link up on Antegren antibody
18 August 2000
Biogen claims victory in interferon beta production lawsuit
17 August 2000
Stock Commentary Europe
3 August 2000
Serono sees 2nd-qtr net income leap 60%
21 July 2000
Avonex sales continue to boost Biogen
13 July 2000
Biogen anger over UK beta interferon move
28 June 2000
Serono plans $2B share offer, US filing
23 June 2000
Teva's Copaxone close to EU approval
5 June 2000
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
